18 results on '"Iguchi, Motofumi"'
Search Results
2. A unique hinge binder of extremely selective aminopyridine-based Mps1 (TTK) kinase inhibitors with cellular activity
3. A Phase 2 Study of S-588410 Maintenance Monotherapy for Platinum-Treated Advanced or Metastatic Urothelial Carcinoma
4. Relationship between baseline clinical characteristics and efficacy of lusutrombopag in thrombocytopenic patients with chronic liver disease: post hoc analysis of two placebo-controlled phase 3 trials
5. Suppression of immunoglobulin production by a novel dihydroorotate dehydrogenase inhibitor, S-2678
6. Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2
7. Phase II open-label study of S-588410 as maintenance monotherapy after first-line platinum-containing chemotherapy in patients with advanced or metastatic urothelial carcinoma.
8. Combination Therapy of Interleukin-2 and Sorafenib Improves Survival Benefits and Prevents Spontaneous Pulmonary Metastasis in Murine Renal Cell Carcinoma Models
9. Antitumor Efficacy of Recombinant Human Interleukin-2 Combined with Sorafenib Against Mouse Renal Cell Carcinoma
10. Relationship between baseline clinical characteristics and efficacy of lusutrombopag in thrombocytopenic patients with chronic liver disease: post hoc analysis of two placebo-controlled phase 3 trials.
11. Soluble HLA-associated peptide from PSF1 has a cancer vaccine potency
12. Discovery of novel 5-alkynyl-4-anilinopyrimidines as potent, orally active dual inhibitors of EGFR and Her-2 tyrosine kinases
13. Discovery of Imidazo[1,2-b]pyridazine Derivatives: Selective and Orally Available Mps1 (TTK) Kinase Inhibitors Exhibiting Remarkable Antiproliferative Activity
14. Synthesis and evaluation of novel pyrimidine-based dual EGFR/Her-2 inhibitors
15. S-222611, an oral reversible tyrosine kinase inhibitor of EGFR and HER2. A representative histological image of the colon treated with S-222611 (25 mg/kg)
16. Indazole-Based Potent and Cell-Active Mps1 Kinase Inhibitors: Rational Design from Pan-Kinase Inhibitor Anthrapyrazolone (SP600125)
17. Diaminopyridine-Based Potent and Selective Mps1 Kinase Inhibitors Binding to an Unusual Flipped-Peptide Conformation
18. Indazole-BasedPotent and Cell-Active Mps1 Kinase Inhibitors: Rational Design fromPan-Kinase Inhibitor Anthrapyrazolone (SP600125).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.